Page last updated: 2024-12-05

dipalmitoylphosphatidic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

dipalmitoylphosphatidic acid: RN given refers to parent cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

dihexadecanoyl phosphatidic acid : A phosphatidic acid in which the phosphatidyl acyl groups are both palmitoyl (hexadecanoyl). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3099
CHEMBL ID1606485
CHEBI ID78105
SCHEMBL ID2718544
MeSH IDM0099147

Synonyms (49)

Synonym
CBIOL_001831
hexadecanoic acid, 1-[(phosphonooxy)methyl]-1,2-ethanediyl ester
1,2-dipalmitoy
(1)-1-[(phosphonooxy)methyl]-1,2-ethanediyl dihexadecanoate
palmitin, 1,2-di-, phosphate
LMGP10010012
pa(16:0/16:0)[rac]
1,2-dipalmitoyl-rac-glycerophosphoric acid
palmitin, 1,2-di-, dihydrogen phosphate
19698-29-4
BIO1_001095
BIO1_000606
BIO2_000656
BIO1_000117
BIO2_000176
IDI1_033926
dipalmitoylphosphatidic acid
NCGC00161388-01
NCGC00161388-02
KBIO3_000351
KBIO2_005312
KBIO2_002744
KBIOGR_000176
KBIO2_000176
KBIO3_000352
KBIOSS_000176
BSPBIO_001456
NCGC00161388-03
HMS1989I18
HMS1791I18
2,3-bis(palmitoyloxy)propyl dihydrogen phosphate
einecs 243-238-2
(1)-2,3-bis(palmitoyloxy)propyl dihydrogen phosphate
einecs 225-873-7
pa(32:0)
SCHEMBL2718544
3-(phosphonooxy)propane-1,2-diyl dihexadecanoate
dihexadecanoyl phosphatidic acid
1,2-dipalmitoylglycero-3-phosphate
CHEBI:78105 ,
1,2-dihexadecanoylglycero-3-phosphate
CHEMBL1606485
HMS3402I18
2,3-bis-(palmitoyloxy)propyl dihydrogen phosphate
pa(16:0_16:0)
Q27147644
DTXSID00864003
PD047005
pa 16:0_16:0

Research Excerpts

Overview

Dipalmitoylphosphatidic acid (DPPA) is a bioactive phospholipid.

ExcerptReferenceRelevance
"Dipalmitoylphosphatidic acid (DPPA) is a bioactive phospholipid."( Dipalmitoylphosphatidic acid inhibits tumor growth in triple-negative breast cancer.
Chen, J; Duan, YF; He, XD; Li, JC; Qi, CL; Wang, L; Yang, YX; Zhang, M; Zhang, QQ; Zhou, DL, 2017
)
2.62

Dosage Studied

ExcerptRelevanceReference
"Compared to conventional parenteral formulations injectable depot formulations, owing to a sustained drug release, offer several advantages, such as a reduced dosing frequency - and consequent improved compliance - or a predictable release profile."( Study on the in situ aggregation of liposomes with negatively charged phospholipids for use as injectable depot formulation.
Luciani, P; Rahnfeld, L; Steiniger, F; Thamm, J; van Hoogevest, P, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
phosphatidic acidA derivative of glycerol in which one hydroxy group, commonly but not necessarily primary, is esterified with phosphoric acid and the other two are esterified with fatty acids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
survival motor neuron protein isoform dHomo sapiens (human)Potency0.70790.125912.234435.4813AID1458
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (73)

TimeframeStudies, This Drug (%)All Drugs %
pre-199017 (23.29)18.7374
1990's16 (21.92)18.2507
2000's25 (34.25)29.6817
2010's13 (17.81)24.3611
2020's2 (2.74)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.13 (24.57)
Research Supply Index4.36 (2.92)
Research Growth Index4.49 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.13)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other77 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]